Canadian trial tests monkeypox drug in outpatients

NCT ID NCT05534165

Terminated Disease control Sponsor: Marina Klein Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Canadian study tests whether the antiviral drug tecovirimat (TPOXX) helps non-hospitalized adults with monkeypox recover faster. About 120 participants will receive either the drug or a placebo. The main goal is to see how quickly skin lesions heal and whether running such a trial in Canada is practical.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tecovirimat (also known as TPOXX), an antiviral drug
What this could lead to: If it works, this could provide an effective treatment for monkeypox that speeds up recovery and reduces symptoms in outpatients.
What could go wrong: This is a feasibility study with only 120 participants, so results may not be definitive. The trial is currently suspended, and tecovirimat may not work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monkeypox

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MONKEYPOX

Contacts and locations

Locations

St. Michael's Hospital

Toronto, Ontario, M5B 1W8, Canada
St. Paul's Hospital, BC Centre for Excellence in HIV/AIDS

Vancouver, British Columbia, V6Z 1Y6, Canada
Toronto General Hospital

Toronto, Ontario, M5G 2N2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.